The latest announcement is out from Myriad Genetics (MYGN).
Myriad Genetics, Inc. and its current and former directors and officers faced shareholder derivative complaints alleging breaches of fiduciary duties. These complaints were consolidated and a settlement has been proposed, which includes corporate governance reforms and attorney fees capped at $950,000. The settlement awaits court approval, with a hearing scheduled for August 6, 2024.
See more insights into MYGN stock on TipRanks’ Stock Analysis page.
